drugset / Trial / NCT04831502

Bioavailability and Food Effect Study of Two Formulations of TAK-906

NCT04831502

Phase 1 Withdrawn Takeda
RandomizedCrossoverOpen-labelOther

Summary

The aim of this study is to understand how TAK-906 tablets and capsules are processed by the body in healthy adults under fasting conditions and also how TAK-906 tablets are processed by the body when taken with a high fat high calorie breakfast compared to fasting. This study will require participants to stay at the clinical research unit for about 3 weeks to be monitored after receiving TAK-906.

Timeline

Start
2021-04-02
Primary completion
2022-02-02
Completion
2022-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Trazpiroben Small molecule 50 mg Oral

Indications

No indication recorded.